I have been ringing the alarm on the Dilution Gap since the original deep dive, where I called it a CRITICAL RED FLAG. In March I said it was “still flashing neon red.” In May I upgraded it to “a mathematical certainty.” Today the company itself put it in writing.
The Q2 10-Q contains a new risk factor and a new liquidity note stating there is substantial doubt as to the Company’s ability to continue as a going concern. That is not my editorializing — that is management’s own disclosure language, and it is the single most consequential line in this filing.
The counterweight, filed in the same breath: enrollment of the platinum-resistant/refractory (PROC) ovarian cohort for the primary analysis is complete. The clinical clock has stopped ticking. The financial one hasn’t.
The going-concern flag. Management determined current cash “may not be sufficient to fund planned operations for at least one year from the date of this Quarterly Report.” The implication: Once this language appears, it does not quietly disappear next quarter — it comes off only when a financing, a partnership, or a licensing deal lands. It also creates a nasty reflexive loop the filing itself acknowledges: the going-concern statement “could adversely affect the price of our common stock and our ability to raise new capital.” They have to raise into a disclosure that makes raising harder.
Cash: $79.4M at June 30, 2026. Down from $93.5M at March 31 and $112.9M at year-end 2025. First-half operating cash burn was $34.3M, or roughly $17.1M/quarter — actually better than the $19.7M Q1 pace I flagged in May. Why it matters: They are economizing. R&D fell to $14.7M in Q2 from $18.4M a year ago, driven by lower CRO costs, which is exactly what you’d expect once enrollment closes. Burn is decelerating into the NDA. That’s the one genuinely encouraging line on the balance sheet.
Runway guidance unchanged: through Q2 2027. NDA submission still targeted Q1 2027. The implication: The one-quarter buffer I described in May is still the shape of the problem. At ~$17M/quarter, cash at NDA submission lands somewhere near $45M — better than the ~$35M I modeled, but nowhere near enough to sit through an FDA review cycle, build a commercial organization, and manufacture launch supply.
The ATM still hasn’t fired. Again. Zero shares sold under the ATM in Q2 2026, same as Q1. $113.8M remains available alongside the $200M shelf. Share count is essentially flat at 53,460,432 (up 128,666 from year-end, all ESPP and option exercises). The implication: Two consecutive quarters of an untouched ATM while the stock drifts from $1.42 to $1.26. Management is holding out for a higher print. With a going-concern flag now attached, that bet just got materially harder to win.
PROC enrollment complete. The registrational Phase 2 monotherapy portion — single-arm, 2000 mg once-daily, ~70 sites — has finished enrolling the ovarian patients who will constitute the primary analysis. Why it matters: The denominator is now fixed. See below.
Nothing in Item 5.02, nothing in 10b5-1. No director or officer adopted or terminated a trading arrangement during Q2. CEO David Mack, who bought 220,000+ shares on the open market last year, did not step up again below $1.50. That’s the tell I said I’d be watching for. It didn’t come.
This is the part the market underweighted today, and it deserves translation.
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.